AGTR1 recombinant proteins and antibodies

Angiotensin II Receptor Type 1 (AGTR1) is a G-protein coupled receptor that is widely expressed in various tissues, including the heart, blood vessels, kidneys, and brain. It is a key receptor in the angiotensin II (Ang II) signaling pathway. Angiotensin II, a potent vasoconstrictor, activates the AGTR1 receptor to regulate blood pressure, fluid balance, salt metabolism, and cardiovascular function. Due to its critical role in blood pressure regulation and cardiovascular health, AGTR1 has become an important therapeutic target for diseases such as hypertension, heart failure, and kidney diseases.

Overactivation of AGTR1 is closely linked to various diseases, particularly hypertension, heart failure, kidney disease, and atherosclerosis. As a result, AGTR1 antagonists, such as angiotensin receptor blockers (ARBs), have become important drugs for treating these conditions. For example, common ARBs like Losartan and Irbesartan block the AGTR1 receptor to lower blood pressure and improve cardiovascular health. Additionally, AGTR1 is also implicated in the progression of complications from diabetes, kidney damage, and cardiac fibrosis.

Currently, drug development targeting AGTR1 is focused on optimizing existing ARB drugs while exploring new therapeutic approaches. Newer AGTR1 antagonists are being developed that not only block the effects of angiotensin II but may also offer additional multi-target effects. For instance, some researchers are developing AGTR1 antagonists with anti-inflammatory properties, which may alleviate cardiovascular diseases caused by inflammation. Moreover, AGTR1’s role in kidney diseases has prompted many companies to explore it as a potential target for treating chronic kidney disease (CKD) and diabetic kidney disease (DKD).

In terms of industry positioning, several biopharmaceutical companies have entered the field of AGTR1 drug development, especially in the treatment of cardiovascular and kidney diseases. Some companies are developing more selective and long-acting AGTR1 antagonists, while also exploring combination therapies with other cardiovascular drugs, such as ACE inhibitors. As our understanding of AGTR1’s role in various diseases deepens, more innovative drugs and therapeutic strategies are expected to emerge, advancing the treatment of hypertension, heart failure, and other related diseases. In conclusion, AGTR1 is an important therapeutic target with a broad drug development outlook. With ongoing research, innovative treatments targeting AGTR1 are likely to play an increasingly crucial role in the management of hypertension, cardiovascular diseases, and kidney disorders.

To assist in the development of drugs targeting AGTR1, DIMA BIOTECH can now provide full-length AGTR1 recombinant membrane protein developed by its nanodisc membrane protein platform. AGTR1 nanodisc is an optimal solution for screening small molecules targeting AGTR1 with its natural structure. Furthermore, DIMA BIOTECH has also prepared a AGTR1 single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.